Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


Translational CNS Summit

21 May 2013 - 23 May 2013 - Boston, MA, USA



Bookmark and Share


Increase the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.


Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical developmente the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.

Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical development



Further information
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!